Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?| Positive | ||
| Negative | ||
| Uncertain | ||
| Constraining | ||
| Legalese | ||
| Litigous | ||
| Readability |
H.S. freshman Good
|
|
New words:
Aegera, altered, assume, bankruptcy, Biotech, Canada, chemotherapy, concluded, deducted, director, earn, earned, employee, ensure, evaluation, expansion, family, formation, genome, HPV, HYB, implicated, Investigational, manner, method, Micrologix, milestone, NOL, optimization, optimize, ORI, papilloma, passage, percentage, Pillar, power, processed, Quebec, redeemed, regular, resistance, responsibility, responsible, separate, summarized, whichever, work, workforce, worldwide, XIAP
Filing tables
Filing exhibits
- 10-Q Quarterly report
- 10.1 EX-10.1 Executive Stock Option Agmnt - 1,260,000
- 10.2 EX-10.2 Executive Stock Option Agmnt - 550,000
- 10.3 EX-10.3 Executive Stock Option Agmnt - 500,000
- 10.4 EX-10.4 Consulting Agreement Dated October 1, 2002
- 99.1 EX-99.1 Certifications Pursuant to Section 906
- PDF Courtesy PDF Copy
ACGN similar filings
External links